Tapewire

Nasdaq · USD

HBIO

HARVARD BIOSCIENCE INC

Export transactions ↓
Tapewire entity
7369
SEC CIK
0001123494
Parsed reports
266

Last 12 months

Inside the activity.

5 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202650
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
June 09, 2026 Filed Jun 11, 2026 16:56 UTC GrantCommon Stock 16,556 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-004060 · ownership.xml · nonDerivative · entry 1

Snider William · CIK 0001340831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,556

F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.

F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 14:03 UTC GrantCommon Stock 16,556 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-004058 · ownership.xml · nonDerivative · entry 1

DENELSKY STEPHEN J · CIK 0001204320 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,556

F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026.

F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 14:02 UTC GrantCommon Stock 16,556 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-004057 · ownership.xml · nonDerivative · entry 1

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,556

F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.

F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 14:00 UTC GrantCommon Stock 16,556 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-004056 · ownership.xml · nonDerivative · entry 1

Benson Seth Benjamin · CIK 0002078549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,556

F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.

F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
June 09, 2026 Filed Jun 12, 2026 15:52 UTC GrantCommon Stock 16,556 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-004082 · ownership.xml · nonDerivative · entry 1

Eade Katherine A. · CIK 0001721318 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,669

F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.

F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
March 20, 2026 Filed Mar 23, 2026 13:48 UTC
Duke John DDirector · Chief Executive Officer
GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-001843 · ownership.xml · nonDerivative · entry 1

Duke John D · CIK 0002071593 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

F1 · balance_after: See remarks

Read SEC document
March 20, 2026 Filed Apr 1, 2026 13:57 UTC
Frost Mark TChief Financial Officer
GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001171843-26-002156 · ownership.xml · nonDerivative · entry 1

Frost Mark T · CIK 0001310262 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,500

F1 · balance_after: Includes (a) an award granting 30,000 restricted stock units (RSUs) that will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 5,000 shares of common stock purchased on March 16, 2026, (c) 10,000 RSUs that will vest on May 12, 2026, and (d) 2,500 shares of common stock beneficially owned by the Reporting Person.

F2 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 RSUs referenced in Footnote 1(c) were previously reported as covering 100,000 RSUs and the 2,500 shares of common stock referenced in Footnote 1(d) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 18:13 UTC PurchaseCommon Stock 10,000 $4.87 $48,700.00
Disclosure

SEC source: 0001171843-26-001732 · ownership.xml · nonDerivative · entry 1

DENELSKY STEPHEN J · CIK 0001204320 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

F1 · balance_after: Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026.

F2 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 11:31 UTC PurchaseCommon Stock 8,475 $4.85 $41,103.75
Disclosure

SEC source: 0001171843-26-001689 · ownership.xml · nonDerivative · entry 2

Snider William · CIK 0001340831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

F2 · price: The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

F4 · balance_after: Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026.

F5 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
March 16, 2026 Filed Mar 17, 2026 21:56 UTC
Duke John DDirector · Chief Executive Officer
PurchaseCommon Stock 5,000 $5.01 $25,050.00
Disclosure

SEC source: 0001171843-26-001645 · ownership.xml · nonDerivative · entry 1

Duke John D · CIK 0002071593 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

F1 · balance_after: Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) an award of 50,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person and (c) an award of 50,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.

F2 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 50,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 500,000 restricted stock units and the 50,000 restricted stock units referenced in Footnote 1(c) were previously reported as covering 500,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 11:31 UTC PurchaseCommon Stock 12,525 $4.99 $62,499.75
Disclosure

SEC source: 0001171843-26-001689 · ownership.xml · nonDerivative · entry 1

Snider William · CIK 0001340831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,525

F1 · price: The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

F3 · balance_after: Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026.

F5 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
March 16, 2026 Filed Apr 1, 2026 13:44 UTC
Frost Mark TChief Financial Officer
PurchaseCommon Stock 5,000 $5.00 $25,000.00
Disclosure

SEC source: 0001171843-26-002155 · ownership.xml · nonDerivative · entry 1

Frost Mark T · CIK 0001310262 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

F1 · balance_after: Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) 10,000 restricted stock units that will vest on May 12, 2026, and (c) 2,500 shares of common stock beneficially owned by the Reporting Person.

F2 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 100,000 restricted stock units and the 2,500 shares of common stock referenced in Footnote 1(c) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Read SEC document
December 17, 2025 Filed Dec 31, 2025 01:48 UTC GrantCommon Stock 110,000 $0.00 $0.00
Disclosure

SEC source: 0001171843-25-008127 · ownership.xml · nonDerivative · entry 1

Snider William · CIK 0001340831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on December 17, 2026.

Read SEC document
September 05, 2025 Filed Oct 7, 2025 17:28 UTC GrantCommon Stock 110,000 $0.00 $0.00
Disclosure

SEC source: 0001171843-25-006325 · ownership.xml · nonDerivative · entry 1

DENELSKY STEPHEN J · CIK 0001204320 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on September 5, 2026.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 18:39 UTC Disposition to issuerCommon Stock 113,366 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-080209 · tm2523890-1_4seq1.xml · nonDerivative · entry 6

Green James W · CIK 0001400121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,452,566

F6 · shares: Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer.

F7 · balance_after: This total includes 375,005 RSUs with performance based vesting conditions.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 18:39 UTC Disposition to issuerCommon Stock 66,036 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-080209 · tm2523890-1_4seq1.xml · nonDerivative · entry 5

Green James W · CIK 0001400121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,565,905

F5 · shares: Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 18:39 UTC Tax withholdingCommon Stock 11,540 $0.53 $6,104.66
Disclosure

SEC source: 0001104659-25-080209 · tm2523890-1_4seq1.xml · nonDerivative · entry 4

Green James W · CIK 0001400121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,631,968

F4 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 18:39 UTC Disposition to issuerCommon Stock 119,332 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-080209 · tm2523890-1_4seq1.xml · nonDerivative · entry 3

Green James W · CIK 0001400121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,643,508

F3 · shares: Represents forfeiture of time-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 18:39 UTC Tax withholdingCommon Stock 33,200 $0.53 $17,562.80
Disclosure

SEC source: 0001104659-25-080209 · tm2523890-1_4seq1.xml · nonDerivative · entry 2

Green James W · CIK 0001400121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,762,840

F2 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 18:39 UTC Disposition to issuerCommon Stock 49,048 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-080209 · tm2523890-1_4seq1.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,796,040

F1 · shares: Represents forfeiture of time-based restricted stock units ("RSUs") granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer.

Read SEC document
August 08, 2025 Filed Aug 12, 2025 01:09 UTC
Duke John DDirector · Chief Executive Officer
GrantCommon Stock 500,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-076302 · tm2523107-1_4seq1.xml · nonDerivative · entry 2

Duke John D · CIK 0002071593 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

F2 · shares: Represents an award of 500,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.

F3 · balance_after: Includes the awards described in footnotes (1) and (2) above.

Read SEC document
August 08, 2025 Filed Aug 12, 2025 01:09 UTC
Duke John DDirector · Chief Executive Officer
GrantCommon Stock 500,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-076302 · tm2523107-1_4seq1.xml · nonDerivative · entry 1

Duke John D · CIK 0002071593 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

F1 · shares: Represents an award of 500,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person.

Read SEC document
July 16, 2025 Filed Jul 18, 2025 20:33 UTC GrantCommon Stock 110,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-069051 · tm2521202-3_4seq1.xml · nonDerivative · entry 1

Eade Katherine A. · CIK 0001721318 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 421,126

F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 311,126 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
July 16, 2025 Filed Jul 18, 2025 20:32 UTC GrantCommon Stock 110,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-069048 · tm2521202-2_4seq1.xml · nonDerivative · entry 1

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

Read SEC document
July 16, 2025 Filed Jul 26, 2025 01:38 UTC GrantCommon Stock 110,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-070938 · tm2521788-2_4seq1.xml · nonDerivative · entry 1

Benson Seth Benjamin · CIK 0002078549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

Read SEC document
May 12, 2025 Filed May 14, 2025 19:52 UTC
Frost Mark TInterim CFO
GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-048461 · tm2514961-2_4seq1.xml · nonDerivative · entry 1

Frost Mark T · CIK 0001310262 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

F1 · shares: Represents 100,000 restricted stock units that will vest on May 12, 2026.

F2 · balance_after: Includes (a) 100,000 restricted stock units that will vest on May 12, 2026, and (b) 25,000 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
March 19, 2025 Filed Mar 21, 2025 20:50 UTC
Cote JenniferChief Financial Officer
Tax withholdingCommon Stock 5,687 $0.69 $3,916.07
Disclosure

SEC source: 0001104659-25-026705 · tm259984-2_4seq1.xml · nonDerivative · entry 1

Cote Jennifer · CIK 0001960481 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,019

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on March 19, 2025.

F2 · balance_after: Includes (a) 8,964 RSUs that will vest on December 29, 2025, (b) 23,867 RSUs that will vest in two equal installments on March 19, 2026 and 2027, (c) 35,800 RSUs with performance based vesting conditions tied to achievements by the Company of certain performance criteria, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 64,526 shares of common stock (which includes 4,496 shares acquired on December 31, 2024 under the Issuer's Employee Stock Purchase Plan) beneficially owned by the Reporting Person.

Read SEC document
March 19, 2025 Filed Mar 21, 2025 20:49 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 38,413 $0.69 $26,451.19
Disclosure

SEC source: 0001104659-25-026702 · tm259984-1_4seq1.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,845,088

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested on March 19, 2025.

F2 · balance_after: Includes (a) 117,713 RSUs that will vest on December 29, 2025, (b) 143,198 RSUs that will vest in two equal installments on March 19, 2026 and 2027, (c) 554,407 RSUs with performance based vesting conditions and (d) 2,029,770 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:15 UTC
Green James WDirector · Chief Executive Officer
Disposition to issuerCommon Stock 145,365 $0.00 $0.00
Disclosure

SEC source: 0000921895-25-000025 · form412799001_01032025.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,883,501

F1 · shares: Represents forfeiture of performance-based restricted stock units ("RSUs") granted to the Reporting Person on March 1, 2022 based on the final determination of the applicable performance conditions.

F2 · balance_after: Includes (a) 117,713 RSUs that will vest on December 29, 2025, (b) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (c) 554,407 RSUs with performance based vesting conditions and (d) 1,996,584 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
December 29, 2024 Filed Dec 31, 2024 21:02 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 25,310 $1.98 $50,113.80
Disclosure

SEC source: 0000921895-24-003052 · form412799001gre_12312024.xml · nonDerivative · entry 2

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,028,866

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested on December 29, 2024.

F2 · balance_after: Includes (a) 117,713 RSUs that will vest on December 29, 2025, (b) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (c) 699,772 RSUs with performance based vesting conditions and (d) 1,996,584 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
December 29, 2024 Filed Dec 31, 2024 21:02 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 56,915 $1.98 $112,691.70
Disclosure

SEC source: 0000921895-24-003052 · form412799001gre_12312024.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,054,176

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested on December 29, 2024.

Read SEC document
December 29, 2024 Filed Dec 31, 2024 21:01 UTC
Cote JenniferChief Financial Officer
Tax withholdingCommon Stock 3,797 $1.98 $7,518.06
Disclosure

SEC source: 0000921895-24-003051 · form412799001cot_12312024.xml · nonDerivative · entry 2

Cote Jennifer · CIK 0001960481 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,210

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on December 29, 2024.

F2 · balance_after: Includes (a) 8,964 RSUs that will vest on December 29, 2025, (b) 35,800 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (c) 35,800 RSUs with performance based vesting conditions tied to achievements by the Company of certain performance criteria, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 53,784 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
December 29, 2024 Filed Dec 31, 2024 21:01 UTC
Cote JenniferChief Financial Officer
Tax withholdingCommon Stock 4,731 $1.98 $9,367.38
Disclosure

SEC source: 0000921895-24-003051 · form412799001cot_12312024.xml · nonDerivative · entry 1

Cote Jennifer · CIK 0001960481 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,007

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on December 29, 2024.

Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:02 UTC
Green James WDirector · Chief Executive Officer
PurchaseCommon Stock 10,000 $2.91 $29,100.00
Disclosure

SEC source: 0000921895-24-001418 · form412799001_06142024.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,111,091

F1 · balance_after: Includes (a) 235,427 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (b) 52,346 RSUs that will vest on December 29, 2024, (c) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (d) 699,772 RSUs with performance based vesting conditions and (e) 1,908,749 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:02 UTC
Green James WDirector · Chief Executive Officer
PurchaseCommon Stock 20,000 $3.07 $61,400.00
Disclosure

SEC source: 0000921895-24-001362 · form412799001_06072024.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,101,091

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.03 to $3.12, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · balance_after: Includes (a) 235,427 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (b) 52,346 RSUs that will vest on December 29, 2024, (c) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (d) 699,772 RSUs with performance based vesting conditions and (e) 1,898,749 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:24 UTC
LOY BERTRANDDirector
GrantCommon Stock 56,575 $0.00 $0.00
Disclosure

SEC source: 0000921895-24-001307 · form412799001loy_05232024.xml · nonDerivative · entry 1

LOY BERTRAND · CIK 0001197452 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,575

F1 · shares: Represents an award of 56,575 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:23 UTC GrantCommon Stock 45,872 $0.00 $0.00
Disclosure

SEC source: 0000921895-24-001306 · form412799001loe_05232024.xml · nonDerivative · entry 1

Loewald Thomas W · CIK 0001538555 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,311

F1 · shares: Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 249,439 shares of common stock held by the Reporting Person.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:22 UTC GrantCommon Stock 45,872 $0.00 $0.00
Disclosure

SEC source: 0000921895-24-001305 · form412799001ead_05232024.xml · nonDerivative · entry 1

Eade Katherine A. · CIK 0001721318 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,126

F1 · shares: Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 265,254 shares of common stock held by the Reporting Person.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:20 UTC GrantCommon Stock 45,872 $0.00 $0.00
Disclosure

SEC source: 0000921895-24-001304 · form412799001ala_05232024.xml · nonDerivative · entry 1

EDRICK ALAN I · CIK 0001195340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,911

F1 · shares: Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 228,039 shares of common stock held by the Reporting Person.

Read SEC document
March 06, 2024 Filed Mar 7, 2024 21:04 UTC
Cote JenniferChief Financial Officer
Tax withholdingCommon Stock 9,920 $4.11 $40,771.20
Disclosure

SEC source: 0001193805-24-000334 · e619343_4-cote.xml · nonDerivative · entry 3

Cote Jennifer · CIK 0001960481 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,738

F1 · shares: Shares withheld by the Company solely to cover tax obligations upon the vesting of 29,880 restricted stock units ("RSUs").

F4 · balance_after: Includes (a) the awards described in footnotes (2) and (3) above, (b) 17,928 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (c) 11,171 RSUs that will vest on December 29, 2024, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 42,177 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:04 UTC
Cote JenniferChief Financial Officer
GrantCommon Stock 35,800 $0.00 $0.00
Disclosure

SEC source: 0001193805-24-000334 · e619343_4-cote.xml · nonDerivative · entry 2

Cote Jennifer · CIK 0001960481 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,658

F3 · shares: The number of RSUs represents the target number of RSUs that may be earned based on achievement by the Company of certain performance criteria. The actual number of RSUs awarded may vary between 0% and 150% of the target, depending on the Company's performance. The performance period will end on December 31, 2026.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:04 UTC
Cote JenniferChief Financial Officer
GrantCommon Stock 35,800 $0.00 $0.00
Disclosure

SEC source: 0001193805-24-000334 · e619343_4-cote.xml · nonDerivative · entry 1

Cote Jennifer · CIK 0001960481 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,858

F2 · shares: Represents an award of RSUs that will vest in three equal installments on March 19, 2025, 2026, and 2027.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:03 UTC
Green James WDirector · Chief Executive Officer
GrantCommon Stock 214,797 $0.00 $0.00
Disclosure

SEC source: 0001193805-24-000333 · e619331_4-green.xml · nonDerivative · entry 2

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,081,091

F2 · shares: The number of RSUs represents the target number of RSUs that may be earned based on achievement by the Company of certain performance criteria. The actual number of RSUs awarded may vary between 0% and 150% of the target, depending on the Company's performance. The performance period will end on December 31, 2026.

F3 · balance_after: Includes (a) the awards described in footnotes (1) and (2) above, (b) 235,427 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (c) 52,346 RSUs that will vest on December 29, 2024, (d) 484,975 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 1,878,749 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:03 UTC
Green James WDirector · Chief Executive Officer
GrantCommon Stock 214,797 $0.00 $0.00
Disclosure

SEC source: 0001193805-24-000333 · e619331_4-green.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,866,294

F1 · shares: Represents an award of restricted stock units ("RSUs") that will vest in three equal installments on March 19, 2025, 2026, and 2027.

Read SEC document
December 31, 2023 Filed Jan 3, 2024 22:18 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 82,790 $5.35 $442,926.50
Disclosure

SEC source: 0000921895-24-000043 · form412799001gre_01032024.xml · nonDerivative · entry 5

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,651,497

F2 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person that vested on December 31, 2023.

F3 · balance_after: Includes (a) 235,427 restricted stock units that will vest in two equal installments on December 29, 2024 and 2025, (b) 52,346 restricted stock units that will vest on December 29, 2024, (c) 484,975 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (d) 1,878,749 shares of common stock beneficially owned by the Reporting Person.

Read SEC document
December 29, 2023 Filed Jan 3, 2024 22:18 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 52,206 $5.35 $279,302.10
Disclosure

SEC source: 0000921895-24-000043 · form412799001gre_01032024.xml · nonDerivative · entry 4

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,734,287

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit awards previously granted to the Reporting Person that vested on December 29, 2023.

Read SEC document
December 29, 2023 Filed Jan 3, 2024 22:18 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 23,216 $5.35 $124,205.60
Disclosure

SEC source: 0000921895-24-000043 · form412799001gre_01032024.xml · nonDerivative · entry 3

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,786,493

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit awards previously granted to the Reporting Person that vested on December 29, 2023.

Read SEC document
December 29, 2023 Filed Jan 3, 2024 22:18 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 28,783 $5.35 $153,989.05
Disclosure

SEC source: 0000921895-24-000043 · form412799001gre_01032024.xml · nonDerivative · entry 2

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,809,709

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit awards previously granted to the Reporting Person that vested on December 29, 2023.

Read SEC document
December 29, 2023 Filed Jan 3, 2024 22:18 UTC
Green James WDirector · Chief Executive Officer
Tax withholdingCommon Stock 24,187 $5.35 $129,400.45
Disclosure

SEC source: 0000921895-24-000043 · form412799001gre_01032024.xml · nonDerivative · entry 1

Green James W · CIK 0001400121 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,838,492

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit awards previously granted to the Reporting Person that vested on December 29, 2023.

Read SEC document
December 29, 2023 Filed Jan 3, 2024 22:17 UTC
Cote JenniferDirector · Chief Financial Officer
Tax withholdingCommon Stock 2,631 $5.35 $14,075.85
Disclosure

SEC source: 0000921895-24-000042 · form412799001cot_01032024.xml · nonDerivative · entry 2

Cote Jennifer · CIK 0001960481 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,058

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit awards previously granted to the reporting person that vested in part on December 29, 2023.

F2 · balance_after: Includes (a) 17,928 restricted stock units that will vest in two equal installments on December 29, 2024 and 2025, (b) 11,171 restricted stock units that will vest on December 29, 2024, (c) 25,862 restricted stock units with performance based vesting conditions tied to relative total shareholder return, (d) 29,880 restricted stock units that will vest on March 6, 2024 and (e) 22,217 shares of common stock beneficially owned by the Reporting Person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.